Timetable - The 2nd Latin America Congress on Controversies to Consensus to Diabetes, Obesity and Hypertension (CODHy)

The 2nd Latin America Congress on
Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)
Rio de Janeiro, Brazil, March 22-25, 2012

Timetable

	Thursday, March 22, 2012
	Welcome Reception - 19:30 Sponsored by Novo Nordisk

Friday, March 23, 2012

Hall A

09:00-10:30

Plenary Session 1

Diabetes, Cardiovascular Diseases and Cancer

Insulin resistance: A multifaceted disease responsible for ASCVD and cancer

Diabetes, obesity and cancer

Diabetes therapy and cancer

Overview of diabetes in Latin America

10:30-11:00

Coffee Break

Hall A

Hall B

Hall C

11:00-12:30

Session 2

Prevention and Early Therapy

Prediabetes therapy: Lifestyle/Drugs

First line therapy in T2D: Combination therapy vs.

Monotherapy:

Session 5
Hypertension Controversies

Should we change the target blood pressure in diabetic patients?
Yes/No

Should we avoid antihypertensive drugs that increase glucose/ obesity?
Yes/No

Session 8
Obesity

Current and future non-surgical weight loss therapy

Are there weight loss-independant effects of upper gastrointestinal tract diversion on diabetes?

How good is sleeve gastrectomy?

Bio Markers in diabetes and obesity

12:30-13:30

Lunch Break

13:30-15:15

Session 3
Utilization of Insulin Therapy by GPs

Are all sulfonylurea (Su) even?
Yes/No

Starting insulin therapy by GP: BASAL vs. Premix
Basal/Premix

Insulin intensification by GP
Yes/No

Session 6
RAAS in Diabetes

Is intracellular RAAS blockade a therapeutic target?

ACEs, ARBs or DRI: what is the best choice?

Is RAAS blockade indicated in every (T2D) patient

Oral Presentations

Session 9
Insulin Resistance/Beta Cell Role in Diabetes Progression

Tools to assess insulin resistance and Beta Cell function

Beta function: Evaluation and clinical applications

Insulin secretion and Insulin resistance: A dynamic interaction

15:15-15:45

Coffee Break

15:45-17:00

Session 4
The Voice of China

Treatment of Type 2 diabetes with traditional Chinese medicine

Relationship of Urinary Bisphenol A Concen-tration to Risk for Prevalent Type 2 Diabetes in Chinese Adults

The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study

Stratifying and tailoring HbA1c control targets for adults with Type 2 diabetes: Interpretation of the consensus proposed by the Chinese Society of Endocrinology

Session 7
Meet the Professor: Metabolic Syndrome

Metabolic Syndrome: Do we need this definition?

Testosterone for the management of Metabolic Syndrome

Intolerance to statin/target HDL

Yes/No

Session 10
New Insights to Neuropathy in T2D

Peripheral Neuropathy and small fibers: Diagnosis and therapeutic approach

CAN: A tool to assess the diagnosis by the diabetologist

The brain: New insights with diabetes, Alzheimer and depression

17:00-19:00

SGLT2 Inhibition and the ‘CODHy’ Controversies: Glycaemic Control and Beyond
Satellite Symposium sponsored by Bristol-Myers Squibb & AstraZeneca
This educational programme is accredited by the Royal College of Physicians of the United Kingdom for 2 credits
Hall C

Saturday, March 24, 2012

Hall A

Hall B

Hall C

09:00-10:30

Session 11
Type 2 Diabetes (T2D)

Can we stop Beta Cell destruction?
Yes/No

Early insulin therapy
Yes/No

Session 15
Hypertension Therapy in T2D

Diabetes and resistant hypertension

Managing combination antihypertensive therapy

What is the fourth drug?

New strategies: Baroreceptor devices and renal denervation

Session 19
Glucose Therapy

Should we aim at normal glycaemia or an individual approach?
Normal glycaemia/
Individual approach

Different goals with different therapies

Algorithm for T2D in Brazil

10:30-11:00

Coffee Break

11:00-12:30

Session 12
Targeting the Kidney
(Supported by an unrestricted educational grant from Boehringer Ingelheim and Eli Lilly and Company)

The kidney and its role in Glucose Homeostasis

Glucosuria as a novel approach in diabetes management

SGLT2 Safety barriers

Session 16
Hypoglycaemia

Good or Bad?
Good/Bad

Similar importance in every patient?
Yes/No

Can it be prevented?
Yes/No

Session 20

Interrelationship Between CVD and Diabetes: Focusing on the Incretin System
(Supported by an unrestricted educational grant from Merck Sharp & Dohme)

The rationale for early and aggressive treatment of CVD risk factors in T2DM

Potential CVD effects of incretin-based therapies

12:30-13:30

Lunch Break

13:30-15:15

Session 13

Oral Presentations

Session 17
New Data on Glycaemic Effects of Incretin Based Therapy in T2D

The vascular system and heart

The brain

The liver

Oral Presentations

Session 21
Bariatric Surgery

Minimal requirements to perform bariatric surgery

Do we have long term data to support efficacy and safety?
Yes/No

Surgery in mild obesity and T2D
1st line/ 2nd line

15:15-15:45

Coffee Break

15:45-16:45

Session 14

Hepatic Manifestations of Metabolic Syndrome: Pathophysiological and Clinical Controversies

Inflammatory manifestations in patienst with metabolic syndrome

Medical treatment of obesity in NASH with diabetes

Diabetic management of T2D and hepatic cirrhosis

Session 18

Diagnosis of T2D in Latin America

Trends and prevalance of T2D in Argentina

New diagnostic non-invasive methods in diabetes screening for Latin America (risk scores and EZScan validation in Latin America)

Session 22
Meet the Professor: Need to control Glycaemic variability

Glycaemic variability is it important?

Do we need continuous glucose monitoring

16:45-17:45

Guided Poster Tour

16:45-17:45

Clinical evidence supporting the protein diet as a tool for the medical management of excess weight: ProKal® Study results
Industrial Satellite Symposium Sponsored by Pronokal
Hall B

Sunday, March 25, 2012

Hall A

09:00-10:30

Plenary Session 23
Impact of Pregnancy Hyperglycemia on Future Cardiovascular Risk Factors

Introduction: GDM definition-implications

Obesity, hypertension and pregnancy

Pharmacological therapy in pregnancy hyperglycemia:
Oral hypoglycemic agents vs. Insulin therapy

Maternal hyperglycemia: future impact on mothers and children

Discussion

10:30-11:00

Coffee Break

11:00-12:30

Plenary Session 24
Global Breakthroughs in the World of Diabetes

Diabetic drug interaction

GLP1, short/ long term safety

Future therapy for obesity and diabetes: Long acting GLP1/ Insulin

Stem Cell therapy: State of the art

Oral Insulin